Precision Biosciences Stock Price, News & Analysis

Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.

News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.

A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.

Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.

Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.

Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.